AllCells - Quality Cells for Quality Science - Distributed in the UK by Caltag Medsystems

AllCells^® - Advance your cell and gene therapy program with high-quality human cellular starting materials and integrated analytics - all in one place.

AllCells^®, a division of Discovery Life Sciences, has been providing high-quality primary cell products and integrated services to support the cell and gene therapy (CGT) industry since 1998. AllCells' RUO and GMP products come with industry-leading viability for optimal consistency and reproducibility.

With over three decades of combined experience serving the CGT market and an unmatched global network of well-characterized, highly engaged recallable donors, AllCells provides a revolutionary set of scalable, end-to-end CGT solutions.

Their scientific experts optimize projects with an innovative, collaborative, flexible, and client-centric approach, providing cell isolation, cell culture, and immunophenotypic and functional profiling services adjacent to donor clinics to help define process analytics and inform decision-making.

See the Products Available:

Leukopaks

AllCells' leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Their leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit.

Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to venipuncture collection or buffy coat isolation. AllCells' leukopaks allow for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability.

AllCells offers made-to-stock (MTS) cryopreserved leukopaks for project flexibility as well as made-to-order (MTO) leukopaks engineered to meet unique project needs.

More about AllCell's Leukopaks

Mobilized Leukopaks

AllCells is the industry leader in supplying mobilized Leukopaks with the shortest lead time on the market. Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche into the circulation. Mobilized peripheral blood, enriched in single-donor CD34+ HSPCs is collected through leukapheresis using the Spectra Optia® Apheresis System's continuous flow centrifugal technology. The ease of collection and high yield of single-donor CD34+ cells is a major advantage to researchers to gain experimental consistency and scalability.

AllCells has six different mobilization regimens available using G-CSF (Neupogen®), plerixafor (Mozobil®), or a combination of the two drugs as well as CD34+ cells isolated from mobilized Leukopaks.

More about AllCell's Mobilized Leukopaks

Bone Marrow

Bone marrow is an excellent source of CD34+ hematopoietic stem and progenitor cells (HSPCs) and mesenchymal stem cells. It is the primary site of hematopoiesis in adults, the process of mature blood cell formation from HSPCs to maintain blood homeostasis.

AllCells' bone marrow products are collected by qualified clinicians from the posterior iliac crest of healthy and consenting donors following IRB-approved protocols. Bone marrow is available in fresh, cryopreserved, or frozen, and in different formats.

More about AllCell's Bone Marrow

Cord Blood

Umbilical Cord Blood is a rich source of primitive CD34+ hematopoietic stem and progenitor cells reported to be more naive with a higher proliferative, engraftment and multipotent potential than those isolated from adult bone marrow. Because of these attributes, cord blood can be a great tool for applications where bypassing HLA mismatch is required. AllCells offers cryopreserved cord blood CD34+ isolated cells from a single umbilical cord or from multiple cord blood units for mixed donor products.

More about AllCell's Cord Blood

Isolated Cell Products

AllCells offers bulk cell isolations of important cell types from single-donor leukapheresis and bone marrow material - standard and sequential immunomagnetic separation protocols are available. Obtain large quantities of quality-controlled cells including CD34+ HSPCs, lymphocyte populations (T cells, B cells, NK cells, and monocytes), and PBMCs for a variety of research and biomedical applications.

Obtaining bulk quantities of highly pure and viable isolated cells from a qualified vendor offers researchers the opportunity to bank cells to support experimental consistency and comparability, and streamlines laboratory workflows.

GMP Products

AllCells' proven capabilities help clients navigate and streamline the complex journey from product development to commercialization. When clinical applications and increased regulatory compliance are required, AllCells' GMP, clinical-grade products are offered to meet the later stages of product development.

Partnering with AllCells for RUO and GMP products to span the entire workflow mitigates timeline and cost delays that could arise from having to revalidate source material and suppliers. This also provides the flexibility and agility to bilaterally transition between pre-clinical and clinical phases to address the dynamic nature of cell therapy product development.

Clinical Grade Mobilized Leukopaks

Clinical Grade Leukopaks

Clinical Grade Bone Marrow

Blog posts

AllCells’ has thousands of well-characterised, highly engaged recallable donors, with specific attributes, at collection sites across the US & Europe.

AllCells’ Pre-Characterised Donor Selection Program expedites screening, selecting & collecting from donors for downstream clinical manufacturing.

Key takeaways from AllCells’ VP of Donor Operations presentation on reframing the donor supply chain ecosystem to support the CGT manufacturing boom.

AllCells and Discovery continue to expand their solutions alongside the CGT industry to help researchers overcome roadblocks.

How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development

AllCells’ has thousands of well-characterised, highly engaged recallable donors, with specific attributes, at collection sites across the US & Europe.

Overcoming the Donor Selection Challenges to Drive Success in Cell and Gene Therapy Development and Commercialisation

AllCells’ Pre-Characterised Donor Selection Program expedites screening, selecting & collecting from donors for downstream clinical manufacturing.

Reframing the Inherent Donor Supply Chain Ecosystem to Support the Imminent CGT Manufacturing Boom: Recap of the Allogeneic Cell Therapies Summit 2023

Key takeaways from AllCells’ VP of Donor Operations presentation on reframing the donor supply chain ecosystem to support the CGT manufacturing boom.

The World’s Largest Apheresis Network Serves as a Catalyst to Advance Cell and Gene Therapies

AllCells and Discovery continue to expand their solutions alongside the CGT industry to help researchers overcome roadblocks.

Category	Title
Human Blood Products Documents	GMP-Compliant Cryopreserved Leukopak	View
AllCells GMP-compliant cryopreserved leukopak products offer the quality and consistency of fresh leukapheresis material with the benefit of extended shelf life and stability for reliable and flexible access to starting material for downstream cell and gene therapy manufacturing, no matter your timeline.
Human Blood Products Documents	GMP-Compliant Cryopreserved Leukopak CATALOG NUMBER: CG, LP, CR, SOLO, 2.5-3.0B	View
Peripheral blood is collected from IRB-consented donors using the continuous flow Spectra Optia® Apheresis System directly into ACD-A anticoagulant at AllCells FDA-registered, IRB-approved collection facilities. Fresh leukapheresis material is immediately processed in adjacent processing facilities. The leukopaks are cryopreserved in CryoStor® CS10 using conduction-cooled controlled rate freezers. All cryopreservation steps occur within class ISO 7 cleanroom with grade A and B zones according to Master Batch Record. GMP-Compliant Cryopreserved Leukopak are quality controlled for pre-cryopreservation cell count and viability using a validated AO/PI protocol and meet the strict quality standards as defined by the FDA (21 CFR 1271) and AABB.
Human Blood Products Documents	T Cell Products for Every Application	View
T cells are the main effector cells of the adaptive immune system. They can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on their cell surface. Differentiated from bone marrow-derived hematopoietic stem cells, T cells migrate to the thymus gland where they mature into CD4 and CD8 T cells. Further differentiation occurs in the periphery of CD4 and CD8 T cells into several distinct subtypes, each with distinct roles during the formation of an immune response. These lymphocytes are of great interest for a wide range of research and translational medicine applications.
Human Blood Products Documents	Case Study: Successful Mobilized Collections from Sickle Cell Trait Donors	View
Cell and gene therapies are at the forefront of medical innovation, transforming how we treat and potentially cure certain diseases that have previously lacked an effective treatment. Robust clinical pipelines and a growing list of FDA-approved therapies brings hope to many patients, placing tremendous pressure on biopharma companies to accelerate development to meet the growing demand. In contrast to traditional biologics (i.e., monoclonal antibodies), the cells themselves are the therapeutic agent. Therefore, clinical success of cell and gene therapies hinges on access to a consistent and high-quality supply of cellular starting material, which are inherently vulnerable to supply chain complications and setbacks. This is further compounded when donors with unique (and potentially rare) attributes are needed. Partnering with an established and reputable supplier like AllCells can bridge the gap and enable the identification of (and collection from) the right donors that can allow companies to move swiftly from therapeutic discovery to commercialization.
Human Blood Products Documents	NK Cells for Every Application	View
Natural killer (NK) cells are members of the innate immune system representing 5-20% of the circulating lymphocytes. Classified as group I Innate Lymphocytes (ILCs), they arise from the same lymphoid progenitor cells as T and B cells and play a critical role in immune surveillance and can mount rapid immune responses to a wide variety of pathological challenges.
Human Blood Products Documents	GMP-Compliant Mobilized Leukopak	View
CD34+ stem cells have the capacity for self-renewal, making them a valuable source of hematopoietic stem and progenitor cells for cell therapies. In fact, allogeneic hematopoietic stem cell (HSC) transplantation has been used routinely as a curative treatment for indications in oncology and regenerative medicine. However, challenges with HLA-matching and potential risk of graft vs. host disease (GvHD) has led to a surge in the development of autologous and allogeneic genetically engineered HSC therapies as alternative treatments. As these programs mature, there is a need for GMP-compliant Mobilized Leukopaks — enriched in high-quality CD34+ cells—to support process validation and qualification. AllCells GMP-compliant Mobilized Leukopaks overcome donor and process variability to mitigate risk in downstream applications to accelerate time-to-market.
Human Blood Products Documents	Bulk Isolation Services	View
The isolation of specific cell populations from blood products via immunomagnetic cell separation remains an integral operation in any research organization to enrich target cells for immunology and other fields in life sciences. Outsourcing this time-consuming process to an external supplier can streamline your labs workflow and liberate in-house personnel to focus on other priorities. Bulk isolation by a qualified vendor provides all the quality assurances of a commercial product without incurring any capital or operational costs in house. Get high-yield cell products from a single-donor source. Standard and sequential isolations are available.
Human Blood Products Documents	Considering the Regulatory Compliance of Starting Biomaterials Early in Cell & Gene Therapy Development Can Mitigate the Cos	View
It is advantageous to identify suitable clinical grade, GMP-compliant raw materials and reliable supply partners early in preclinical development to support rapid and seamless clinical translation of a cell and gene therapy (CGT) candidate. There are very few GMP suppliers who can fulfill the regulatory requirements for donor-sourced materials and identifying one can be a lengthy process. Securing these partnerships early and building in time for vendor evaluation, project discussions and design, documentation, and donor screening can help prevent delays downstream.
Human Blood Products Documents	Technical Bulletin - Human Bone Marrow Aspirate	View
Technical bulletin for HUMAN BONE MARROW ASPIRATE.
Human Blood Products Documents	Searching for Sickle Cell Trait Donors?	View
By leveraging their recruiting expertise, coupled with novel marketing tactics, AllCells industry-leading donor management program recruits and collects from donors with sickle cell trait (SCT), providing a rare resource to bridge the gap for researchers working to treat SCD.